Uy Ear
Stock Analyst at Mizuho
(4.22)
# 432
Out of 5,149 analysts
80
Total ratings
52.08%
Success rate
18.36%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Downgrades: Neutral | $33 → $12 | $10.50 | +14.29% | 7 | Mar 3, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $37 → $35 | $24.76 | +41.36% | 16 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Outperform | $29 → $35 | $22.81 | +53.44% | 16 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $132.38 | +32.20% | 11 | Dec 12, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $4.29 | +342.89% | 4 | Dec 2, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $1 → $10 | $4.84 | +106.61% | 2 | Nov 19, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $16.32 | +59.31% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $30.25 | +48.76% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $32.97 | +69.85% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $23.00 | +269.57% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $7.60 | +426.32% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $248.56 | -83.91% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.30 | +203.03% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.94 | +54.64% | 2 | Mar 1, 2023 |
uniQure
Mar 3, 2026
Downgrades: Neutral
Price Target: $33 → $12
Current: $10.50
Upside: +14.29%
Arcutis Biotherapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $37 → $35
Current: $24.76
Upside: +41.36%
ACADIA Pharmaceuticals
Feb 23, 2026
Upgrades: Outperform
Price Target: $29 → $35
Current: $22.81
Upside: +53.44%
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $132.38
Upside: +32.20%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $4.29
Upside: +342.89%
Relmada Therapeutics
Nov 19, 2025
Upgrades: Outperform
Price Target: $1 → $10
Current: $4.84
Upside: +106.61%
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $16.32
Upside: +59.31%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $30.25
Upside: +48.76%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $32.97
Upside: +69.85%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $23.00
Upside: +269.57%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $7.60
Upside: +426.32%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $248.56
Upside: -83.91%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $3.30
Upside: +203.03%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.94
Upside: +54.64%